Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Colon-specific antigen-p, or CSAp, was originally extracted from GW-39 tumors, which are human colonic carcinomas serially transplanted in golden hamsters, and antibodies to CSAp have been produced in the same animal hosts. By means of immunodiffusion and a hemagglutination-inhibition assay, CSAp has been found to be restricted to adult and fetal small intestine, neoplastic gastric and colonic tissues, inflamed colon, and cystic mucinous tumors of the ovary. CSAp was shown to be distinct from blood group antigens, including Lea and Leb blood group substances, liver ferritin, AFP, CEA, CSA, CMA, ZGM, and BOFA, and to have the electrophoretic mobility of an alpha2-globulin. Gel filtration studies indicated that CSAp in GW-39 tumor, primary human colonic carcinoma, and ovarian cancer mucinous cyst fluid had a peak molecular size range of 70,000--110,000. Quantitation of CSAp in 214 tissue specimens by the hemagglutination-inhibition assay revealed a progressive increase in fetal, inflamed, and neoplastic intestine, such that CSAp in colonic tumors was increased over normal colon tissue. Thus, CSAp appears to be an organ-specific antigen showing increased levels in some gastrointestinal and ovarian neoplasms, as well as in specimens with colitis.
 ...
PMID:Further characterization of CSAp, an antigen associated with gastrointestinal and ovarian tumors. 8 13

Six tumor-associated antigens, cancer antigen 125 (CA125), tissue polypeptide antigen (TPA), ferritin (Fr), carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), and sialyl Lex-i (SLX) were measured simultaneously for the early detection of ovarian cancer. To decrease the number of both false positive and false negative cases in the combination assay, statistical discrimination analysis employing the serum values for appropriate tumor markers has been studied with respect to ovarian cancer by the method of Mahalanobis' generalized distance. The new "ovarian cancer screening test" designed by us has been used in Shizuoka Prefecture since 1988, and 23,307 serum samples have been analyzed. One hundred twenty-seven of 165 ovarian cancer patients were suspected as having cancer by such clinical procedures as pelvic examination and/or ultrasonography, while in 150 patients cancer was detected by the statistical discrimination method. Thirty-one of 38 patients with ovarian cancer overlooked by the clinical procedures could be found by the statistical method. We conclude that clinical procedures and the statistical method can be complementary in detecting patients with this malignancy.
 ...
PMID:[Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance]. 137 32

Six tumor-associated antigens, cancer antigen 125(CA125), tissue polypeptide antigen (TPA), ferritin (Fr), carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), and sialyl Lex-i(SLX) were measured simultaneously for the early detection of ovarian cancer. To decrease both false positive and false negative cases in the combination assay, the value of statistical discrimination analysis employing the serum values of appropriate tumor markers in detecting ovarian cancer was studied by the method of Mahalanobis' generalized distance. The new "ovarian cancer screening test" designed by us has been enforced in Shizuoka Prefecture since 1988, and 23,307 serum samples have been analyzed. Of the 165 ovarian cancer patients 127 patients were suspected as cancer by such clinical procedures as pelvic examination and/or ultrasonography, while 150 patients were detected cancer by the statistical discrimination method. Of the 38 patients with ovarian cancer overlooked by the clinical procedures 31 could be found by the statistical method. We conclude that clinical procedures and the statistical method can be complementary in detecting patients with this malignancy.
 ...
PMID:[Field trial for the early detection of patients with ovarian cancer]. 137 18

Some characteristics of cell biology and the production of various tumor markers were examined using 8 human ovarian cancer cell lines of epithelial origin. Structural abnormalities of chromosomes 1, 3, and 6 were relatively common karyotypic changes among the cell lines. Cytoplasmic estradiol or progesterone receptor was not detected in any of the cell lines. A significant heterogeneity of the production of various tumor markers (ferritin, tissue peptide antigen, carcinoembryonic antigen, carbohydrate antigens 125, and 19-9) was noted among the cell lines grown in culture medium supplemented with serum. Three of the 8 cell lines were adapted to proliferate in completely synthetic serum-free culture medium. In addition to marker substances described above, small amounts of progesterone or human chorionic gonadotropin were produced in 2 of the 3 cell lines grown in serum-free culture medium. These results indicate that various marker substances including tumor markers are not produced consistently by human ovarian cancer cells of epithelial origin.
 ...
PMID:Production of various marker substances in human ovarian cancer cell lines of epithelial origin. 207 56

Blood serum levels of ferritin and trophoblastic globulin were measured by immunoassay in 389 and 114 cases, respectively, suffering malignant or benign tumors of the uterus and ovary as well as in controls. Hyperferritinemia identified at serum ferritin levels in excess of 200 micrograms/l was established in 94% of cases of ovarian cancer, 57%--benign ovarian tumors, 60%--endometrial carcinoma and in 16% of patients with uterine myoma. Patients with ovarian and uterine malignancies were shown to have the highest serum ferritin levels. The study failed to establish an increase in trophoblastic globulin concentration in cases of nontrophoblastic tumors of the genitals. It is suggested that serum ferritin level be measured in patients presenting with ovarian and uterine tumors and in subjects at high risk for ovarian cancer to assure early diagnosis of disease.
 ...
PMID:[Serum ferritin and trophoblastic globulin in genital tumors in women]. 218 Feb 8

Tumour markers are substances that occur at elevated blood levels in patients with certain tumours. When their specificity and sensitivity are known, markers can be used to monitor cancer patients. No single marker is specific and sensitive for a certain tumour, so a tumour-marker combination is used. The efficacy of CA 125, ferritin, TPA and CEA was demonstrated in 162 ovarian cancer patients. With the same combination, we found a statistically significant 91.7% correlation between the clinical course of the disease and the marker profile in 60 further patients. Tumour markers can also help make a prognosis. In 34 patients the marker profile accurately predicated the findings at second-look surgery. Thus, biochemical monitoring may supplant the second-look procedure. 68 patients were followed for a mean of 2.7 years after completion of chemotherapy. In 95.6% the tumour-marker analysis correlated with the clinical and radiologic course. This means that the end of chemotherapy depends on biochemical monitoring, and second-line therapy can be initiated sooner.
 ...
PMID:[Tumor marker combination versus second-look operation in ovarian cancer]. 237 87

Seven tumor markers (CA125, CA19-9, TPA, IAP, CEA, ferritin, LDH) were measured in 24 patients with ovarian cancer. The positive rates in untreated cases of ovarian cancer were 87.5% for CA125, 35.5% for CA19-9, 10% for CEA, 77.8% for IAP, 63.6% for TPA, 28.6% for LDH and 35.3% for ferritin. Among these, CA125 was the most available marker for detecting tumor growth or regression during each respective clinical course by serial measurement. Serial changes in serum alpha-fetoprotein (AFP) levels during treatment were studied among 27 patients with ovarian embryonal carcinoma. AFP decreased with a half-life of about 7 days, and was restored to the normal range within 10 weeks after the initial surgery and chemotherapy (VAC) in all cases. In subsequently fatal cases, AFP rose again during 10 to 30 weeks after the initial treatment.
 ...
PMID:[Significance of tumor markers in the treatment of patients with ovarian malignancies]. 244 93

In order to determine the clinical significance of sialyl SSEA-1 antigen, we compared its usefulness as a tumor marker for ovarian cancer with simultaneously measured CA125, CA19-9, TPA, IAP, CEA and ferritin. The sialyl SSEA-1 antigen in serum was measured by radioimmunoassay with an "FH-6" Otsuka Kit. The immunohistochemical localization of sialyl SSEA-1 antigen in ovarian carcinoma tissues was determined by an immunoperoxidase method using FH-6 monoclonal antibody. Among fifty-one patients with ovarian cancer, the incidence of elevated serum levels was 54.9% with sialyl SSEA-1 antigen, 90.2% with CA125, 48.8% with CA19-9, 78.0% with TPA, 73.1% with IAP, 17.1% with CEA and 63.4% with ferritin. On the other hand, among the patients with uterine malignancies and gynecologic benign tumors, the incidence of elevated sialyl SSEA-1 antigen levels in serum was lower than that of other tumour markers. In the patients with ovarian cancer, the serum levels of sialyl SSEA-1 antigen increased in accordance with the advance of the clinical stage and were also correlated with the effect of therapy. In the examination of immunohistochemical localization of sialyl SSEA-1 antigen, a positive reaction occurred in 10 out of 30 ovarian carcinoma specimens. Intense staining appeared in the secretory materials, in the luminal surface of the glands, and in the cytoplasm of cells. Thus, sialyl SSEA-1 antigen appears to be a useful tumor marker for the diagnosis of ovarian cancer, especially when measured simultaneously with CA125, CA19-9, TPA, ferritin and IAP.
 ...
PMID:Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin. 256 39

We determined Placental-Leucine Aminopeptidase (P-LAP) activity, one of the oncodevelopmental antigens, in sera and in tissues of patients with gynecological cancers. The incidence of P-LAP activity and clinical usefulness of the determination of serum P-LAP activity were studied. The mean level in healthy non-pregnant sera used as controls was 6.0 +/- 2.4mg/dl/h. The mean level of P-LAP activity in patients with benign tumors such as myoma uteri and benign ovarian tumor did not increase in comparison with the controls. The mean level of P-LAP activity in patients with malignant tumor increased with advancing stages, and especially in advanced cervical and ovarian cancer, serum P-LAP levels were significantly higher than in the controls. Serum P-LAP activity correlated with the serum ferritin concentration (r=0.613), but not with the serum alpha-fetoprotein and serum carcinoembryonic antigen concentration. Serial measurements of serum P-LAP activities in patients with gynecological cancer showed that serum P-LAP activity might reflect the progress of cervical and ovarian cancer. Tissue P-LAP activities in 29 ovarian cancers were compared with those in normal tissues. Tissue P-LAP activities in 26 cases out of 29 increased to twice as high as the mean activities in 10 normal ovaries. Our present results suggest the possibility of using P-LAP activity as one of tumor markers for gynecological malignant tumors.
 ...
PMID:[The significance of serum leucine aminopeptidase (P-LAP) determination in the gynecological malignancies]. 258 69

Tumour markers are substances that occur at elevated blood levels in patients with certain tumours. When their specificity and sensitivity are known, markers can be used to monitor cancer patients. No single marker is specific and sensitive for a certain tumour, so that a combination of tumour markers is used. The efficacy of CA125, ferritin, TPA and CEA was demonstrated in 162 patients with ovarian cancer. With the same combination, we found a statistically significant correlation (91.7%) between the clinical course of the disease and the marker profile in 60 further patients. Tumour markers can also help make a prognosis. In 34 patients the marker profile accurately predicted the findings at second-look surgery. Thus, biochemical monitoring may supplant the second-look procedure. Sixty-eight patients were followed for a mean of 2.7 years after completion of chemotherapy. In 95.6% of these cases the tumour-marker analysis correlated with the clinical and radiological course. This means that the end of chemotherapy depends on biochemical monitoring, and second-line therapy can be initiated sooner.
 ...
PMID:A tumour-marker combination versus second-look surgery in ovarian cancer. I. Clinical experience. 266 Oct 94


1 2 3 Next >>